COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,051 Articles (22,627 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 1534: Articles 15331-15340  | Next

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster
Wu, K., Choi, A., Koch, M., Ma, L., Hill, A., Nunna, N., Huang, W., Oestreicher, J., Colpitts, T., Bennett, H., Legault, H., Paila, Y., Nestorova, B., Ding, B., Pajon, R., Miller, J., Leav, B., Carfi, A., McPhee, R., Edwards, D.
10.1101/2021.05.05.21256716 — Posted: 2021-05-06 Discussion: Onsite
SARS-CoV-2 infections and hospitalizations among immigrants in Norway: significance of occupation, household crowding, education, household income and medical risk. A nationwide register study
Labberton, A. S., Godoy, A. A., Elgersma, I. H., Strand, B. H., Telle, K., Arnesen, T. M., Nygard, K. M., Indseth, T.
10.1101/2021.05.04.21256575 — Posted: 2021-05-06
Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study
Mahil, S. K., Yates, M., Yiu, Z. Z., Langan, S. M., Tsakok, T., Dand, N., Mason, K. J., McAteer, H., Meynall, F., Coker, B., Vincent, A., Urmston, D., Vesty, A., Kelly, J., Lancelot, C., Moorhead, L., Bachelez, H., Capon, F., Contreras, C. R., De La Cruz, C., Di Meglio, P., Gisondi, P., Jullien, D., Lambert, J., Naldi, L., Norton, S., Puig, L., Spuls, P., Torres, T., Warren, R. B., Waweru, H., Weinman, J., Brown, M. A., Galloway, J. B., Griffiths, C. M., Barker, J. N., Smith, C. H.
10.1101/2021.05.04.21256507 — Posted: 2021-05-06
Estimating vaccine efficacy against transmission via effect on viral load
Kennedy-Shaffer, L., Kahn, R., Lipsitch, M.
10.1101/2021.05.03.21256556 — Posted: 2021-05-06 Discussion: Onsite
The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses
Fohse, F. K., Geckin, B., Overheul, G. J., van de Maat, J., Kilic, G., Bulut, O., Dijkstra, H., Lemmers, H., Sarlea, S. A., Reijnders, M., Hoogerwerf, J., ten Oever, J., Simonetti, E., van de Veerdonk, F. L., Joosten, L. A. B., Haagmans, B. L., van Crevel, R., Li, Y., van Rij, R. P., GeurtsvanKessel, C., de Jonge, M. I., Dominguez-Andres, J., Netea, M. G.
10.1101/2021.05.03.21256520 — Posted: 2021-05-06 Discussion: Onsite
Modelling upper respiratory viral load dynamics of SARS-CoV-2
Challenger, J. D., Foo, C. Y., Wu, Y., Moradi Marjaneh, M., Liew, F., Thwaites, R. S., Okell, L. C., Cunnington, A. J.
10.1101/2021.05.01.21256182 — Posted: 2021-05-06
1H, 13C and 15N resonance assignment of the SARS-CoV-2 full-length nsp1 protein and its mutants reveals its unique secondary structure features in solution.
Agback, P., Agback, T., Frolova, E. I., Frolov, I., Dominguez, F.
10.1101/2021.05.05.442725 — Posted: 2021-05-05
Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant
Yinda, K. C., Port, J., Bushmaker, T., Fischer, R., Schulz, J., Holbrook, M., Shaia, C., de Wit, E., van Doremalen, N., Munster, V.
10.1101/2021.05.05.442780 — Posted: 2021-05-05
SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant
Yadav, P. D., Mohandas, S., Shete, A. M., Nyayanit, D. A., Gupta, N., Patil, D. Y., Sapkal, G. N., Potdar, V., Kadam, M., kumar, A., Kumar, S., Suryavanshi, D., Mote, C. S., Abraham, P., Panda, S., Bhargava, B.
10.1101/2021.05.05.442760 — Posted: 2021-05-05
ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation
Konduri, K. S., Pattisapu, R., Pattisapu, J., Konduri, G. G., Zwetchkenbaum, J., Roy, B., Barman, M., Frazier, A., Hurst, B. L., Duzgunes, N.
10.1101/2021.05.05.442779 — Posted: 2021-05-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).